American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Fixed-duration epcoritamab + R(2) drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the EPCORE NHL-2 trial
    Meeting Abstract

    Falchi, L.; Balari, A. S.; Leppä, S.; Vermaat, J. S. P.; Nijland, M.; Christensen, J. H.; de Vos, S.; Holte, H.; Merryman, R. W.; Lugtenburg, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Non-driver genomic alterations and venous thromboembolism in myeloproliferative neoplasms
    Meeting Abstract

    Ajufo, H.; Leader, A.; Derkach, A.; Chrysafi, P.; Singh, R.; Rampal, R.; Mantha, S.; Zwicker, J. I.
    Blood (2024)

    Fulltext@MSK | Save
  • Increased fiber intake results in better overall survival and lower GI-aGVHD in allo-HCT recipients and pre-clinical GVHD models
    Meeting Abstract

    Paredes, J.; Fei, T.; Dai, A.; Ramos, R.; Adintori, P.; Kousa, A.; Nguyen, C. L.; Victor, K.; Ghale, R.; Pohl, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • TMPRSS6 antisense oligonucleotide therapy reverses inflammation in Jak2(V617F) mutant mice
    Meeting Abstract

    Levy, M.; Li, H.; Dunbar, A.; Huang, Z.; Park, Y.; Lu, M.; Phattalung, P. N.; Planoutene, M.; Casu, C.; Rivella, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Delayed Trp53 activation protects DNMT3A-mutant haematopoietic stem cells from inflammatory attrition
    Meeting Abstract

    Marando, L.; Giotopoulos, G.; Madrigal, P.; Azazi, D. M. A.; Asby, R.; Calleja-Cervantes, M. E.; Lara-Astiaso, D.; Wilson, N. K.; Hannah, R.; Bagri, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Mátrai, Z.; Sanna, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Clonal evolution of lymphoid malignancies following the mutagenic impact of radiotherapy
    Meeting Abstract

    Diamond, B.; Chahar, D.; Jain, M. D.; Poos, A. M.; Durante, M.; Ziccheddu, B.; Kaddoura, M.; Papadimitriou, M.; Maclachlan, K. H.; Jelinek, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A CD33-deleted allograft (trem-cel) enables post-hematopoietic cell transplant (HCT) maintenance dosing of gemtuzumab ozogamicin (GO) with therapeutic levels of drug exposure and low hematologic and hepatic toxicity in patients with high-risk acute myeloid leukemia (AML)
    Meeting Abstract

    DiPersio, J. F.; Koehne, G.; Shah, N. N.; Bernard, L.; Suh, H. C.; Koura, D.; Perales, M. A.; Tamari, R.; Mushtaq, M. U.; Maakaron, J. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-cell atlas of diffuse large B-cell lymphoma reveals integrated malignant B cell and tumor microenvironment characteristics associated with clinical response
    Meeting Abstract

    Baaklini, S.; Sarrabay, A.; Mazuel, A.; Escaliere, B.; Dong, C.; Barthelemy, C.; Gil, L.; Dahbi, L.; Mossadegh-Keller, N.; Van Acker, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Fixed-duration epcoritamab in combination with bendamustine + rituximab for first-line treatment of follicular lymphoma: Initial results from EPCORE NHL-2 Arm 3
    Meeting Abstract

    Brody, J.; Falchi, L.; Vitolo, U.; Nijland, M.; Offner, F.; Snauwaert, S.; Patah, P.; Marek, J.; Morehouse, C.; Steele, A. J.; more...
    Blood (2024)

    Fulltext@MSK | Save